Seiji Kaku

682 total citations
46 papers, 566 citations indexed

About

Seiji Kaku is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Seiji Kaku has authored 46 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 15 papers in Cardiology and Cardiovascular Medicine and 9 papers in Surgery. Recurrent topics in Seiji Kaku's work include Blood Coagulation and Thrombosis Mechanisms (18 papers), Platelet Disorders and Treatments (14 papers) and Atrial Fibrillation Management and Outcomes (8 papers). Seiji Kaku is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (18 papers), Platelet Disorders and Treatments (14 papers) and Atrial Fibrillation Management and Outcomes (8 papers). Seiji Kaku collaborates with scholars based in Japan, Norway and Portugal. Seiji Kaku's co-authors include Tomihisa Kawasaki, Toichi Takenaka, Shinya Yano, Yuta Taniuchi, Yoshihiro Fujimura, Hiroyuki Koshio, Kazuo Sato, Fukushi Hirayama, Yuzo Matsumoto and Yoshiyuki Iwatsuki and has published in prestigious journals such as Blood, Biochemical Journal and European Journal of Immunology.

In The Last Decade

Seiji Kaku

46 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiji Kaku Japan 15 222 168 136 134 77 46 566
Timothy Mather United States 15 298 1.3× 69 0.4× 231 1.7× 62 0.5× 43 0.6× 17 616
J.L.M.L. van Rijn France 9 388 1.7× 113 0.7× 270 2.0× 43 0.3× 117 1.5× 14 836
Gary Salmon United Kingdom 9 179 0.8× 76 0.5× 91 0.7× 39 0.3× 50 0.6× 11 441
S. V. Thiruvikraman Japan 10 333 1.5× 169 1.0× 104 0.8× 16 0.1× 113 1.5× 15 635
Torao Ishida Japan 12 131 0.6× 72 0.4× 178 1.3× 45 0.3× 38 0.5× 16 513
Jason M. Foulks United States 14 282 1.3× 62 0.4× 428 3.1× 26 0.2× 67 0.9× 31 850
J.S. Rosenberg United States 7 378 1.7× 98 0.6× 134 1.0× 23 0.2× 85 1.1× 8 641
Qiufang Cheng United States 19 815 3.7× 127 0.8× 177 1.3× 27 0.2× 32 0.4× 34 1.3k
Masaharu Aritomi Japan 11 128 0.6× 50 0.3× 177 1.3× 25 0.2× 28 0.4× 13 437
Takanori Moriki Japan 11 184 0.8× 63 0.4× 232 1.7× 24 0.2× 21 0.3× 17 575

Countries citing papers authored by Seiji Kaku

Since Specialization
Citations

This map shows the geographic impact of Seiji Kaku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiji Kaku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiji Kaku more than expected).

Fields of papers citing papers by Seiji Kaku

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiji Kaku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiji Kaku. The network helps show where Seiji Kaku may publish in the future.

Co-authorship network of co-authors of Seiji Kaku

This figure shows the co-authorship network connecting the top 25 collaborators of Seiji Kaku. A scholar is included among the top collaborators of Seiji Kaku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiji Kaku. Seiji Kaku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takasu, Toshiyuki, Shoji Takakura, & Seiji Kaku. (2015). Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes. Folia Pharmacologica Japonica. 145(1). 36–42. 1 indexed citations
2.
Yamashita, Atsushi, Seiji Kaku, Yoshiyuki Iwatsuki, Yujiro Asada, & Toshiyuki Funatsu. (2012). Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models. Thrombosis and Haemostasis. 108(11). 896–902. 7 indexed citations
3.
Iwatsuki, Yoshiyuki, Yumiko Moritani, Takeshi Shigenaga, et al.. (2011). Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. European Journal of Pharmacology. 673(1-3). 49–55. 31 indexed citations
4.
Kaku, Seiji, Toshiyuki Funatsu, Hiroyuki Koshio, et al.. (2007). Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models.. Blood. 110(11). 3155–3155. 7 indexed citations
5.
Koshio, Hiroyuki, Fukushi Hirayama, Tsukasa Ishihara, et al.. (2004). Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorganic & Medicinal Chemistry. 12(9). 2179–2191. 14 indexed citations
6.
Koshio, Hiroyuki, Fukushi Hirayama, Tsukasa Ishihara, et al.. (2004). Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives. Bioorganic & Medicinal Chemistry. 12(20). 5415–5426. 12 indexed citations
7.
Kokubo, Satoshi, et al.. (2003). Interleukin-11 Acts Synergistically with Bone Morphogenetic Protein-2 to Accelerate Bone Formation in a Rat Ectopic Model. Journal of Interferon & Cytokine Research. 23(4). 203–207. 18 indexed citations
8.
Hashimoto, Shigehiro, Y. Matsumoto, Hisako Tsuji, et al.. (2002). The effect of pulsatile shear flow on thrombus formation and hemolysis. 4. 2461–2462. 8 indexed citations
9.
Hirayama, Fukushi, Hiroyuki Koshio, Tsukasa Ishihara, et al.. (2002). Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-Bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates. Bioorganic & Medicinal Chemistry. 10(8). 2597–2610. 17 indexed citations
10.
Moritani, Yumiko, Kazuo Sato, Takeshi Shigenaga, et al.. (2002). Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist. European Journal of Pharmacology. 439(1-3). 43–52. 4 indexed citations
11.
Suzuki, Kenichi, Yumiko Moritani, Hiroshi Arai, et al.. (2002). Pharmacodynamics and pharmacokinetics of YM128, a GPIIb/IIIa antagonist prodrug. Drug Development Research. 55(3). 149–161. 3 indexed citations
12.
Kaku, Seiji, Kazuo Umemura, Atsuhiro Mizuno, et al.. (1998). Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. European Journal of Pharmacology. 345(2). 185–192. 29 indexed citations
13.
Kaku, Seiji, Kazuo Umemura, Atsuhiro Mizuno, Tomihisa Kawasaki, & Mitsuyoshi Nakashima. (1997). Evaluation of the disintegrin, triflavin, in a rat middle cerebral artery thrombosis model. European Journal of Pharmacology. 321(3). 301–305. 13 indexed citations
14.
Suzuki, Kenichi, Yumiko Sakai, Yuta Taniuchi, et al.. (1997). Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. European Journal of Pharmacology. 336(2-3). 169–176. 11 indexed citations
15.
Kawasaki, Tomihisa, Kenichi Suzuki, Seiji Kaku, et al.. (1996). Synergistic effect of aurintricarboxylic acid and triflavin in a photochemically induced thrombosis model in rats. European Journal of Pharmacology. 312(1). 69–73. 1 indexed citations
16.
Kawasaki, Tomihisa, Y Sakai, Y Taniuchi, et al.. (1996). Biochemical characterization of a new disintegrin, flavostatin, isolated from Trimeresurus flavoviridis venom. Biochimie. 78(4). 245–252. 21 indexed citations
17.
Kaku, Seiji, Shinya Yano, Tomihisa Kawasaki, et al.. (1996). Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. General Pharmacology The Vascular System. 27(3). 435–439. 4 indexed citations
18.
Yano, Shinya, Kenichi Suzuki, Masao Katoh, et al.. (1994). Epitopes and Biological Activities of Two Monoclonal Antibodies to Platelet Integrin αIIbβ3. The Journal of Biochemistry. 116(4). 778–786. 16 indexed citations
19.
Kawasaki, Tomihisa, Masao Katoh, Seiji Kaku, et al.. (1993). Thrombolytic Activity of a Novel Modified Tissue-Type Plasminogen Activator, YM866, in a Canine Model of Coronary Artery Thrombosis. The Japanese Journal of Pharmacology. 63(1). 9–16. 13 indexed citations
20.
Katoh, Masahito, et al.. (1991). THROMBOLYTIC ACTIVITY OF YM866, A NOVEL ANALOG OF T-PA, IN A CANINE MODEL OF CORONARY-ARTERY THROMBOSIS. Thrombosis and Haemostasis. 65(6). 1337. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy Mather Breakdown of academic impact, for papers by J.L.M.L. van Rijn Breakdown of academic impact, for papers by Gary Salmon Breakdown of academic impact, for papers by S. V. Thiruvikraman Breakdown of academic impact, for papers by Torao Ishida Breakdown of academic impact, for papers by Jason M. Foulks Breakdown of academic impact, for papers by J.S. Rosenberg Breakdown of academic impact, for papers by Qiufang Cheng Breakdown of academic impact, for papers by Masaharu Aritomi Breakdown of academic impact, for papers by Takanori Moriki
Rankless by CCL
2026